Abstract:Recent and advanced methodologies have enhanced the understanding of the immune system features in multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, facilitating the development of personalised therapies. The current collection of articles offers new insights into MS pathology and immunology, identifying therapeutic targets and biomarkers. The articles explore various topics, including immunological biomarkers for predicting treatment success, risks of developing secondary autoimmune conditions, PML, and resistance to disease-modifying therapies. The studies also contribute to elucidating some of the pathological roles of cytotoxic B and T cells, dysfunctional humoral regulatory immunity, and inflammatory cascades triggered by EBV reactivation in the CNS. Additionally, the collection highlights emerging biomarkers of disease activity, offering a comprehensive view of the latest advancements in MS research. Out of the submitted works, nineteen articles were accepted and included in this special issue. Below, we outline the key findings from each study. Several studies have used experimental autoimmune encephalomyelitis (EAE) animal models to explore potential MS treatments. Tang et al. found that T-cell immunoglobulin mucin domain 3 (Tim-3), expressed on immune cells like T cells and macrophages, may inhibit MHC-II-mediated autoantigen presentation and CD4+ T cell activation, influencing EAE outcomes. Targeting the Tim-3/MHC-II signalling pathway could offer new therapeutic options for MS. Hou and Yuki characterised two CCR6+CD4 T cell subsets, showing that one has cytotoxic markers and Th17-related molecules, while another expresses IFNγ and GM-CSF, both contributing to CNS inflammation. These cells could be key targets for future MS therapies.Hu Lu, Peng-Fei and colleagues indicated that lower levels of fibroblast growth factor (FGF) 23 in the blood are associated with an increased risk of MS, although further investigation is needed to confirm FGF23 as a potential target for treating MS and to understand the mechanism by which FGF23 contributes to the risk of MS.The overview by Meier et al. suggests a central role for Epstein-Barr virus (EBV) in the dysregulation of immune responses and neuronal damage seen in multiple sclerosis (MS). After EBV reactivation in latent B-cells, it could trigger immune complexes and anti-EBNA1-IgG production, leading to a cascade of immune responses involving T, B, NK cells, and cytokines (Type-I IFN, TNF-α, IL-6, -10, -17A). This causes localised inflammation, which, combined with a compromised blood-brain barrier, leads to CNS glia activation and inflammatory lesions. Additionally, this process may activate endogenous viral sequences (MSRV, HERV-K/-W, HHV6A), further intensifying CNS inflammation.Several studies have highlighted the role of long non-coding RNAs (lncRNAs) in neurodegenerative diseases. Tamizkar et al. found that the differential expression of five specific lncRNAs in the blood can distinguish Parkinson's disease (PD) patients from healthy donors. In multiple sclerosis (MS), Jalalei et al. identified 52 upregulated, 37 downregulated, and 11 stable lncRNAs in MS patients, suggesting that lncRNA dysregulation may contribute to neuronal death through unknown RNA-based mechanisms. Additionally, bioinformatic analysis by Sabaie et al. revealed that lncRNA SNHG1 might regulate protein processing in T-cell signaling in relapsing-remitting MS (RRMS) patients, although further research is needed to understand the molecular mechanisms underlying neurodegeneration.Yalachkov et al. highlight the importance of examining peripheral and central inflammation markers at MS diagnosis to understand their connection to depressive symptoms Additionally, investigation from Meng Li et al. suggests that IL-17A, Del-1, and Resolvin D1 may co-regulate MS progression, providing insights into therapeutic targets and patient prognosis. Furthermore, a prognostic model using microarray gene expression data shows promise for effectively classifying MS patients and could serve as a valuable diagnostic tool (Haoran Li et al.).

Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis

Comparing Single-Cell Transcriptomes of Blood and Cerebrospinal Fluid Leukocytes in Multiple Sclerosis

Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes

Single-cell profiling reveals periventricular CD56bright NK cell accumulation in multiple sclerosis

Single-Cell Transcriptome Profiling Unravels Distinct Peripheral Blood Immune Cell Signatures of RRMS and MOG Antibody-Associated Disease

Single-cell transcriptome analysis of diffuse large B cells in cerebrospinal fluid of central nervous system lymphoma

Systems Analysis of Immune Changes after B-cell Depletion in Autoimmune Multiple Sclerosis

Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis

Antigen specificity of clonally-enriched CD8+ T cells in multiple sclerosis

Antigen-specificity of clonally-enriched CD8+ T cells in multiple sclerosis

Neuronal vulnerability and multilineage diversity in multiple sclerosis

Gene expression and alternative splicing analysis in a large-scale Multiple Sclerosis study

TCR repertoire diversity in Multiple Sclerosis: High-dimensional bioinformatics analysis of sequences from brain, cerebrospinal fluid and peripheral blood

Cerebrospinal Fluid and Peripheral Blood Lymphomonocyte Single-Cell Transcriptomics in a Subject with Multiple Sclerosis Acutely Infected with HIV

Integrating transcriptomic datasets across neurological disease identifies unique myeloid subpopulations driving disease‐specific signatures

A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis

Single-cell profiling indicates a high similarity between immune cells in the cerebrospinal fluid and in meningeal ectopic lymphoid tissue in experimental autoimmune encephalomyelitis

Uncovering immune characteristics of neurons in the context of multiple sclerosis and experimental autoimmune encephalomyelitis

Editorial: Community series in reassessing the immune system contribution in multiple sclerosis: therapeutic target, biomarkers of disease and immune pathogenesis, volume II

A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis

Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity